Brief: Fusen Pharmaceutical Company Sees Decrease In Profit Attributable For Fy2019 By Over 45%
16/03/2020 12:45
March 16 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* EXPECTED TO RECORD A DECREASE IN PROFIT ATTRIBUTABLE FOR
FY2019
BY OVER 45%
* EXPECTED RESULT DUE TO INCREASED INVESTMENTS IN RESEARCH
AND
DEVELOPMENT, AMONG OTHER THINGS
Source text for Eikon: urn:newsml:reuters.com:*:nHKS88BvH8
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA